Fbxo22-mediated KDM4B degradation determines selective estrogen receptor modulator activity in breast cancer

The agonistic/antagonistic biocharacter of selective estrogen receptor modulators (SERMs) can have therapeutic advantages, particularly in the case of premenopausal breast cancers. Although the contradictory effects of these modulators have been studied in terms of crosstalk between the estrogen rec...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The Journal of clinical investigation 2018-12, Vol.128 (12), p.5603-5619
Hauptverfasser:	Johmura, Yoshikazu, Maeda, Ichiro, Suzuki, Narumi, Wu, Wenwen, Goda, Atsushi, Morita, Mariko, Yamaguchi, Kiyoshi, Yamamoto, Mizuki, Nagasawa, Satoi, Kojima, Yasuyuki, Tsugawa, Koichiro, Inoue, Natsuko, Miyoshi, Yasuo, Osako, Tomo, Akiyama, Futoshi, Maruyama, Reo, Inoue, Jun-Ichiro, Furukawa, Yoichi, Ohta, Tomohiko, Nakanishi, Makoto
Format:	Artikel
Sprache:	eng
Schlagworte:	Androgens Biomedical research Breast cancer Cardiovascular disease Care and treatment Deoxyribonucleic acid DNA DNA methylation Enhancers Epidermal growth factor ErbB-2 protein Estrogen receptors Estrogens F-box protein Ligands Lysine Receptors Selective estrogen receptor modulators Senescence Signal transduction Src protein Steroid hormones Tamoxifen Therapeutic applications Transcription activation
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!